MURR Opens Global Access to NCA Lutetium-177, Producing Year-Round Supply

The University of Missouri Research Reactor has opened its no-carrier-added Lutetium-177 to the global marketplace, marking the first time MURR's GMP NCA Lu-177 product will be available to buyers outside the United States. The announcement, made March 9, extends year-round production of the medical isotope to research, clinical, and commercial customers worldwide.

MURR had already established itself as the premier U.S. supplier of Lu-177 over the past several years, but the domestic focus leaves a significant portion of demand unaddressed. The GMP product is produced 52 weeks per year, a continuous cadence that positions MURR to reliably supply international customers without seasonal gaps.

Executive Director Matt Sanford framed the expansion around the accelerating pipeline of targeted cancer treatments. "There is a growing demand for Lutetium-177 for research, clinical trials and commercial products as more cancer fighting drugs are developed," Sanford said. "MURR is the only end-to-end producer of Lu-177 in the United States, and we are expanding our focus. In addition to supplying commercial quantities of NCA Lu-177 for use in FDA-approved drugs, we will now meet the needs of researchers and clinical-stage companies."

The clinical case for Lu-177 centers on its mechanism. Lutetium-177 is a reactor-produced medical radioisotope that has proven effective in targeted cancer therapies; radiopharmaceuticals containing it deliver precise, high-energy radiation directly to tumors by emitting therapeutic beta particles. The no-carrier-added designation matters here because NCA Lu-177 contains minimal stable lutetium isotope contamination, maximizing specific activity and making it particularly valuable in high-precision radiopharmaceutical manufacturing.

By positioning itself as the sole end-to-end U.S. producer and now opening that supply chain internationally, MURR is staking out a central role in what Sanford described as a growing global demand curve. Researchers at early clinical stages and established commercial manufacturers alike will now be able to source GMP NCA Lu-177 directly from the Columbia, Missouri reactor, with production running through every week of the calendar year.